The paradox of Pulmonary Vascular Resistance: restoration of pulmonary capillary recruitment as a sine qua non for true therapeutic success in PAH
In this conference, Dr. Langleben will discuss normal lung circulatory function, the abnormalities that occur in pulmonary hypertension, how we assess lung vascular perfusion, and how novel therapies are improving lung hemodynamics.
In collaboration with Merck Canada Inc.
Monday December 9, 2024 – 4 p.m.
4 p.m. to 5 p.m.: Conference
5 p.m. to 6 p.m.: Networking cocktail
CRCHUM Amphitheatre 900, Saint-Denis Street, 5th floor
R05.212A and R05.212B
About the speaker
David Langleben, MD Professor,
Faculty of Medicine, McGill University
Director, Pulmonary Vascular Disease Center, Cardiology division Jewish General Hospital
Dr. David Langleben is a Professor in the Faculty of Medicine at McGill University and former Chief of Cardiology at the Jewish General Hospital. He founded and directs the Pulmonary Vascular Disease Centre, the first pulmonary hypertension clinic in Canada. His research interests include pulmonary vascular metabolism; pulmonary vascular cell behavior and function; vascular cell biology; the epidemiology of pulmonary hypertension; and the development of new drugs for pulmonary hypertension.
About CRCHUM's Prestige conferences
The CRCHUM Prestige Conferences are presented by world-renowned speakers in their field of expertise.
This Prestige conferences offer a broad perspective on a scientific topic in a language that is clear and accessible to all participants. They are mainly aimed at the scientific community, including participants who have no prior knowledge of the topic.
In collaboration with
CRCHUM Prestige Conference held on December 9, 2024
Categories
CRCHUM events
